This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 1
  • /
  • Zai Lab announces first patient treated in Greater...

Zai Lab announces first patient treated in Greater China in PANOVA-3 phase III pivotal trial.

Read time: 1 mins
Published:14th Jan 2022
Zai Lab Limited a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase III pivotal trial of Tumor Treating Fields in patients with pancreatic cancer.

PANOVA-3 is a global, open-label, randomized Phase III trial evaluating the efficacy of Tumor Treating Fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer. The trial is expected to enroll approximately 556 patients. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, resectability rate, and toxicity.

Condition: Pancreatic Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.